Sanofi riliprubart setback puts VITALIZE trial and CIDP strategy under sharper focus
Find out how Sanofi’s riliprubart Phase 3 trial halt could reshape CIDP drug development and complement inhibition strategy.
Pharma & Biotech
Pharma & Biotech
Oral complement therapy for myasthenia gravis? Novartis’ iptacopan enters the neurology arena
Novartis gains FDA orphan status for iptacopan in myasthenia gravis. Explore how this oral complement inhibitor could challenge biologics in neurology.